QTP104 25ug: 1 Clinical Trial

Study to Assess Safety, Reactogenicity and Immunogenicity of the repRNA(QTP104) Vaccine Against SARS-CoV-2(COVID-19)

Condition(s):COVID-19; SARS-CoV-2Last Updated:May 25, 2023Active, not recruiting

Clinical Trials by Category

Clinical Trials Alphabetically

About

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.